NASD · Healthcare · Biotechnology · USA
MBX Biosciences Inc is a mid cap company (market value between $2 billion and $10 billion) in the Biotechnology industry.
MBX Biosciences is a clinical-stage biopharmaceutical company developing precision peptide therapies for endocrine and metabolic disorders. Its proprietary PEP platform creates peptides with extended action profiles and low peak-to-trough ratios. Its pipeline includes canvuparatide for chronic hypoparathyroidism, obesity candidates, and imapextide for post-bariatric hypoglycemia.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the MBX Biosciences Inc stock.
Not valued: We cannot value this company yet.
17 more funds hold it; the full list is part of the paid plan.
129 more in this industry show a wider margin of safety.
We do not publish a verdict on MBX yet. We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.
We do not publish one (as of the 2026-11-17 close). We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.